[et_pb_section fb_built=”1″ admin_label=”Listings” module_id=”zielgruppe” _builder_version=”4.27.5″ _module_preset=”default” background_color=”#FFFFFF” background_enable_image=”off” background_size=”custom” background_image_width=”90%” background_position=”bottom_right” top_divider_height=”51px” locked=”off” collapsed=”on” global_colors_info=”{}”][et_pb_row use_custom_gutter=”on” gutter_width=”3″ _builder_version=”4.27.5″ _module_preset=”default” width=”100%” custom_margin=”||30px||false|false” custom_padding=”||||false|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_post_title meta=”off” featured_image=”off” _builder_version=”4.27.5″ _module_preset=”default” title_text_color=”#10344C” title_font_size=”45px” custom_margin=”||15px|||” global_colors_info=”{}” theme_builder_area=”post_content”][\/et_pb_post_title][et_pb_text _builder_version=”4.27.5″ _module_preset=”1f09816e-184e-4ce5-a4cf-b39c52c423ca” text_font=”–et_global_body_font||||||||” text_text_color=”#10344C” text_font_size=”20px” text_line_height=”1.8em” ul_line_height=”1.8em” custom_margin=”||||false|false” text_font_size_tablet=”15px” text_font_size_phone=”14px” text_font_size_last_edited=”on|phone” header_font_size_tablet=”55px” header_font_size_last_edited=”off|desktop” global_colors_info=”{}”]<\/p>\n
Dies ist eine Phase-2-Studie, in der die Wirksamkeit und Sicherheit eines neuen Medikaments namens SAR441566 bei Erwachsenen mit mittelschwerem bis schwerem Morbus Crohn untersucht wird. Verschiedene Dosierungen von SAR441566 werden mit einem Placebo (Scheinmedikament) verglichen, um herauszufinden, welche am besten wirkt.<\/p>\n
Erwachsene mit einer Diagnose von mittelschwerem bis schwerem Morbus Crohn.<\/p>\n
Bis zu 59 Wochen, bestehend aus:<\/p>\n
Die Hauptstudie umfasst 12 Wochen Einleitungsbehandlung und 40 Wochen Erhaltungsphase.
Einige Teilnehmende k\u00f6nnen an einer offenen Behandlungsphase (bis zu 40 Wochen) teilnehmen, in der alle das Studienmedikament erhalten.<\/p>\n
Sanofi
ClinicalTrials.gov ID: NCT06637631<\/p>\n
[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.27.5″ _module_preset=”default” background_color=”#FFFFFF” width=”100%” custom_padding=”50px|50px|50px|50px|true|true” border_radii=”on|35px|35px|35px|35px” box_shadow_style=”preset1″ box_shadow_color=”rgba(170,201,207,0.34)” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.27.5″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.5″ _module_preset=”1f09816e-184e-4ce5-a4cf-b39c52c423ca” text_font=”–et_global_body_font||||||||” text_text_color=”#10344C” text_font_size=”20px” text_line_height=”1.8em” ul_line_height=”1.8em” header_text_align=”center” header_2_text_align=”center” custom_margin=”||||false|false” text_font_size_tablet=”15px” text_font_size_phone=”14px” text_font_size_last_edited=”on|phone” header_font_size_tablet=”55px” header_font_size_last_edited=”off|desktop” global_colors_info=”{}”]<\/p>\n
[\/et_pb_text][et_pb_code _builder_version=”4.27.5″ _module_preset=”default” global_colors_info=”{}”]